Zydus Lifesciences: The financial results for the period ended September 30, 2026
Zydus Lifesciences (ZYDUSLIFE) filed a disclosure titled "The financial results for the period ended September 30, 2026". The company is valued at about ₹1.24 lakh crore.
What happened
Zydus Lifesciences (ZYDUSLIFE) filed a disclosure with the exchanges on 4 November 2026 at 12:19 PM titled "The financial results for the period ended September 30, 2026".
Company snapshot
Zydus Lifesciences is a large-cap company in the Healthcare sector, with a market value of about ₹1.24 lakh crore.
The stock last traded at ₹1,240.6, against a 52-week range of ₹835.5–₹1,266.6 (2.0% below the high).
Before this filing the shares had moved +8.3% over the month and +9.8% over three months. Average daily turnover over the last 20 sessions was about ₹161 crore.
Promoters held 75.01% at the end of Q1 FY27. Foreign institutions owned 6.88% and domestic institutions 11.27%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 6,574 | 1,466.8 | 14.58 |
| Q2 FY26 | 6,123 | 1,258.6 | 12.51 |
| Q3 FY26 | 6,865 | 1,042.1 | 10.36 |
| Q4 FY26 | 7,587 | 1,272.5 | 12.65 |
| Q1 FY27 | 8,017 | 939.8 | 9.35 |
What history shows
BCEIE's records show 2 previous results filings from the company since May 2026.
After those filings, the stock gained 7.7% on average the next trading day and was down 0.3% on average after five days (2 filings with price data).
Across 300 similar disclosures by other Healthcare companies, shares moved +1.3% on average the next day and +2.0% over five days; 56% of them rose the next day.
Market-wide, 10,609 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
| Date | Filing | Next day | 5 days |
|---|---|---|---|
| 11 Aug 2026 | Board Meeting Outcome for Unaudited Financial Results For The… | +7.7% | −0.3% |
| 11 Aug 2026 | Unaudited Financial Results For The Quarter Ended On June 30, 2026 | +7.7% | −0.3% |
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
- 4 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Zydus Lifesciences Gets USFDA Approval for Hormone Patch
- ZYDUSLIFE Share Price Today - Zydus Life Science on NSE/BSE
- ZYDUSLIFE Outlook for the Week
- Zydus Lifesciences gets USFDA nod for menopause treatment drug
- Zydus Lifesciences Secures USFDA Final Approval for Menopause Treatment Patch with USD 45.7 Million US...
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.